{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T03:55:14Z","timestamp":1768794914322,"version":"3.49.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.ijrobp.2019.11.418","type":"journal-article","created":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T18:18:49Z","timestamp":1580753929000},"page":"939-947","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Phase I Trial of Weekly Cabazitaxel with Concurrent Intensity Modulated Radiation and Androgen Deprivation Therapy for the Treatment of High-Risk Prostate Cancer"],"prefix":"10.1016","volume":"106","author":[{"given":"Jianqing","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert B.","family":"Den","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Greenspan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy N.","family":"Showalter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean H.","family":"Hoffman-Censits","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Costas D.","family":"Lallas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edouard J.","family":"Trabulsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard G.","family":"Gomella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark D.","family":"Hurwitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Leiby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam P.","family":"Dicker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. Kevin","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2019.11.418_bib1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/pcan.2013.46","article-title":"Very-high-risk localized prostate cancer: Definition and outcomes","volume":"17","author":"Sundi","year":"2014","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ijrobp.2019.11.418_bib2","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bju.14780","article-title":"Radical prostatectomy or radiotherapy for high- and very high-risk prostate cancer: A multidisciplinary prostate cancer clinic experience of patients eligible for either treatment","volume":"124","author":"Reichard","year":"2019","journal-title":"BJU Int"},{"key":"10.1016\/j.ijrobp.2019.11.418_bib3","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ijrobp.2015.10.056","article-title":"Very high-risk localized prostate cancer: Outcomes following definitive radiation","volume":"94","author":"Narang","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.11.418_bib4","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2007.12.4008","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study","volume":"26","author":"Berthold","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2019.11.418_bib5","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2019.11.418_bib6","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: Long-term survival analysis of the randomized phase III E3805 CHAARTED trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2019.11.418_bib7","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2019.11.418_bib8","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1200\/JCO.18.02158","article-title":"Effect of chemotherapy with docetaxel with androgen suppression and radiotherapy for localized high-risk prostate cancer: The randomized phase III NRG Oncology RTOG 0521 trial","volume":"37","author":"Rosenthal","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2019.11.418_bib9","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1002\/cncr.30620","article-title":"Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology\/RTOG study 0621","volume":"123","author":"Hurwitz","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2019.11.418_bib10","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1200\/JCO.2009.26.2543","article-title":"Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer","volume":"28","author":"Auperin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2019.11.418_bib11","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.radonc.2009.04.014","article-title":"Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients","volume":"92","author":"Pignon","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2019.11.418_bib12","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4103\/0973-1482.148702","article-title":"Concurrent adjuvant radiochemotherapy versus standard chemotherapy followed by radiotherapy in operable breast cancer after breast conserving therapy: A meta-analysis","volume":"12","author":"Huang","year":"2016","journal-title":"J Cancer Res Ther"},{"key":"10.1016\/j.ijrobp.2019.11.418_bib13","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1200\/JCO.2004.02.001","article-title":"Phase I trial of weekly docetaxel with concurrent three-dimensional conformal radiation therapy in the treatment of unfavorable localized adenocarcinoma of the prostate","volume":"22","author":"Kumar","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2019.11.418_bib14","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.radonc.2010.08.012","article-title":"Concurrent and adjuvant docetaxel with three-dimensional conformal radiation therapy plus androgen deprivation for high-risk prostate cancer: preliminary results of a multicentre phase II trial","volume":"97","author":"Bolla","year":"2010","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2019.11.418_bib15","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.urolonc.2007.04.003","article-title":"Phase I\/II trial of docetaxel and concurrent radiation therapy in localized high risk prostate cancer (AGUSG 03-10)","volume":"26","author":"Perrotti","year":"2008","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ijrobp.2019.11.418_bib16","doi-asserted-by":"crossref","first-page":"E721","DOI":"10.1111\/j.1464-410X.2012.11536.x","article-title":"Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer","volume":"110","author":"Chen","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.ijrobp.2019.11.418_bib17","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.clgc.2013.11.019","article-title":"Phase I trial of weekly docetaxel, total androgen blockade, and image-guided intensity-modulated radiotherapy for localized high-risk prostate adenocarcinoma","volume":"12","author":"Marshall","year":"2014","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ijrobp.2019.11.418_bib18","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.radonc.2009.08.042","article-title":"IMRT significantly reduces acute toxicity of whole-pelvis irradiation in patients treated with post-operative adjuvant or salvage radiotherapy after radical prostatectomy","volume":"93","author":"Alongi","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2019.11.418_bib19","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.ijrobp.2007.11.060","article-title":"Intensity-modulated radiotherapy of pelvic lymph nodes in locally advanced prostate cancer: Planning procedures and early experiences","volume":"71","author":"Muren","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.11.418_bib20","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.ijrobp.2007.08.003","article-title":"Impact of image guidance on outcomes after external beam radiotherapy for localized prostate cancer","volume":"70","author":"Kupelian","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.11.418_bib21","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.semradonc.2007.07.001","article-title":"Radiation medicine practice in the image-guided radiation therapy era: New roles and new opportunities","volume":"17","author":"White","year":"2007","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2019.11.418_bib22","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1200\/JCO.2016.72.1068","article-title":"Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: A randomized phase III trial-FIRSTANA","volume":"35","author":"Oudard","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2019.11.418_bib23","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ijrobp.2017.02.004","article-title":"Duration of androgen deprivation in locally advanced prostate cancer: Long-term update of NRG Oncology RTOG 9202","volume":"98","author":"Lawton","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.11.418_bib24","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1056\/NEJMoa0810095","article-title":"Duration of androgen suppression in the treatment of prostate cancer","volume":"360","author":"Bolla","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2019.11.418_bib25","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(08)61815-2","article-title":"Endocrine treatment, with\u00a0or\u00a0without radiotherapy, in locally advanced prostate cancer (SPCG-7\/SFUO-3): An open randomised phase III trial","volume":"373","author":"Widmark","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2019.11.418_bib26","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1016\/S0140-6736(11)61095-7","article-title":"Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial","volume":"378","author":"Warde","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2019.11.418_bib27","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary\u00a0tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): A randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2019.11.418_bib28","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4103\/2229-516X.96789","article-title":"Use of Bayesian statistics in drug development: Advantages and challenges","volume":"2","author":"Gupta","year":"2012","journal-title":"Int J Appl Basic Med Res"},{"key":"10.1016\/j.ijrobp.2019.11.418_bib29","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.ijrobp.2015.09.006","article-title":"Survival outcomes of whole-pelvic versus prostate-only radiation therapy for high-risk prostate cancer patients with use of the National Cancer Data Base","volume":"93","author":"Amini","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.11.418_bib30","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/S1470-2045(18)30528-X","article-title":"Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG\/RTOG 9413): Long-term results of a randomised, phase 3 trial","volume":"19","author":"Roach","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2019.11.418_bib31","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.ijrobp.2019.02.045","article-title":"Dose escalation for prostate adenocarcinoma: A long-term update on the outcomes of a phase 3, single institution randomized clinical trial","volume":"104","author":"Pasalic","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.11.418_bib32","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.ijrobp.2016.12.024","article-title":"Continued benefit to\u00a0rectal separation for prostate radiation therapy: Final results\u00a0of\u00a0a phase III trial","volume":"97","author":"Hamstra","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301619345225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301619345225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T09:46:50Z","timestamp":1759744010000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301619345225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0360301619345225"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2019.11.418","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I Trial of Weekly Cabazitaxel with Concurrent Intensity Modulated Radiation and Androgen Deprivation Therapy for the Treatment of High-Risk Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2019.11.418","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}